International legal practice Osborne Clarke has advised Oxular Limited (Oxular) on its £27 million financing led by Forbion Capital Partners with support from the company's existing leading investors.
Oxular is developing technology to transform the treatment of retinal disease, including diabetic macular edema and macular degeneration. It is also developing programs for rare and orphan conditions, including ocular cancers and delivery of gene therapies. The investment will fund Phase 2 human clinical studies commencing later this year.
The Osborne Clarke team was led by Thames Valley based corporate Partner Rob Hayes, with support from Associate Magnus Williams and Paralegal Fern Tawera.
Rob said: "It was a pleasure to work with the company on its recent funding. It is undoubtedly a fantastic endorsement of the company's technology and the management team's hard work and vision to get the business to this stage."
Tom Cavanagh, CEO of Oxular, said: "We were very pleased to have Rob and the team at Osborne Clarke to advise us on the transaction. As always, their advice was clear, concise and commercial. We were working to a tight timetable, so having a proactive and very responsive team was extremely valuable to the process."
Osborne Clarke is recognised as a leading European law firm for companies operating in the life science and healthcare sector team. Its sector team has a strong track record of providing highly sophisticated advice to investors and biotech clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, the biggest pharma and medical devices companies in the market.